To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall market

To analyze the opportunities in the market for stakeholders and provide details of a competitive landscape for market leaders

To forecast the size of the global mycoplasma testing market with respect to four main regions (along with countries), namely, North America, Europe, Asia, and the Rest of the World

To profile the key players in the global market and comprehensively analyze their core competencies and market shares

To track and analyze competitive developments such as agreements, partnerships, acquisitions, product launches, and expansions in the global mycoplasma testing market

Research Methodology

Top-down and bottom-up approaches were used to estimate and validate the size of the market and to estimate the size of various other dependent submarkets. The overall market size was used in the top-down approach to estimate the sizes of other individual markets (mentioned in the market segmentationby product, technique, application, end user, and region) through percentage splits from secondary and primary research. The bottom-up approach was also implemented (wherever applicable) for data extracted from secondary research to validate the market segment revenues obtained. Various secondary sources such as World Bank, World Health Organization, Centers for Disease Control and Prevention (CDC), white papers; articles from recognized authors; gold standard and silver standard websites, directories, and databases; corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations have been used to identify and collect information useful for this extensive commercial study of the mycoplasma testing market. Primary sources such as experts from related industries and suppliers have been interviewed to obtain and verify critical information as well as to assess prospects of the market. The breakdown of profiles of primaries is shown in the figure below:

This report categorizes the global mycoplasma testing market into the following segments:

Mycoplasma Testing Market, by Product

Kits & Reagent

PCR Assay

Nucleic Acid Detection

Elimination Kits & Reagent

Stains

Standards & Controls

Other Kits & Reagent

Services

Instruments

Mycoplasma Testing Market, by Technique

PCR

ELISA

Direct Assay

Indirect Assay

DNA Staining

Microbial Culture Techniques

Enzymatic Methods

Mycoplasma Testing Market, by Application

Cell Line Testing

Virus Testing

End of Production Cells Testing

Other Applications

Mycoplasma Testing Market, by Region

North America

U.S.

Canada

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe (RoE)

Asia

China

Japan

India

Rest of Asia (RoA)

Rest of the World (RoW)

Customization Options:

Company Information: Detailed company profiles of five or more market players

Opportunities Assessment: A detailed report underlining the various growth opportunities presented in the market

The global mycoplasma testing market is expected to reach USD 943.4 Million by 2022 from USD 523.3 Million in 2017, at a CAGR of 12.5%.

The increasing growth of government support for pharmaceutical and biotechnology industries, rising R&D activities in life sciences research, and rising cell culture contamination are expected to drive the growth of this market.

The global market is segmented by product, technique, application, end user, and region. By product, the market is segmented into kits & reagent, services, and instruments. The kits & reagent segment is expected to lead the global market in 2017. The frequent purchase of these consumables as compared to instruments and increasing use of kit-based techniques are the key factors driving the growth of this segment.

On the basis of technique, the market is classified into PCR, ELISA, direct assays, indirect assays, DNA staining, microbial culture techniques, and enzymatic methods. The PCR segment is expected to account for the largest share of the market in 2017 due it the high acceptance rate of PCR, which can be attributed to its accuracy, speed, and flexibility in life sciences research.

On the basis of application, the mycoplasma testing market is segmented into cell line testing, virus testing, end-of-production cell testing, and other applications. Cell line testing segment accounts for the largest segment and is also the fastest growing application segment in the market. Increasing use of cell lines for research and biopharmaceutical production is the major factor driving the growth of this market.

On the basis of end users, the equipment market is segmented into pharmaceutical and biotechnology companies, academic research institutes, contract research organizations (CROs), cell banks, and other end users. In 2017, the pharmaceutical & biotechnology companies segment is expected to account for the largest share and is projected to register the highest rate during the forecast period. R&D investments in the pharmaceutical industry are one of the major factors fueling the growth of this segment.

The global mycoplasma testing market is dominated by North America, followed by Europe. North America will continue to dominate the global market during the forecast period. However, Asia is expected to witness the highest CAGR, with the growth in this market centered at China, Japan, and India. The increase in generics development and manufacturing is a major growth driver for the pharmaceutical industry in this region. Growing government investments in pharmaceutical R&D and the increasing trend of pharmaceutical outsourcing are some factors propelling market growth in the Asian region.

Major industry players expand across geographies via partnerships and acquisitions in the future. Thermo Fisher Scientific Inc., Lonza Group Ltd., Merck KGaA, and Charles River Laboratories International Inc. have been identified as the top players in this market. These companies have a broad product portfolio with comprehensive features. These companies have products for all end users in this segment, a strong geographical presence, and more importantly, focus on continuous product innovations.

To speak to our analyst for a discussion on the above findings, click Speak to Analyst